Cargando…
Challenges in Transition From Childhood to Adulthood Care in Rare Metabolic Diseases: Results From the First Multi-Center European Survey
Inherited Metabolic Diseases (IMDs) are rare diseases caused by genetic defects in biochemical pathways. Earlier diagnosis and advances in treatment have improved the life expectancy of IMD patients over the last decades, with the majority of patients now surviving beyond the age of 20. This has cre...
Autores principales: | Stepien, Karolina M., Kieć-Wilk, Beata, Lampe, Christina, Tangeraas, Trine, Cefalo, Graziella, Belmatoug, Nadia, Francisco, Rita, del Toro, Mireia, Wagner, Leona, Lauridsen, Anne-Grethe, Sestini, Sylvia, Weinhold, Nathalie, Hahn, Andreas, Montanari, Chiara, Rovelli, Valentina, Bellettato, Cinzia M., Paneghetti, Laura, van Lingen, Corine, Scarpa, Maurizio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962750/ https://www.ncbi.nlm.nih.gov/pubmed/33738294 http://dx.doi.org/10.3389/fmed.2021.652358 |
Ejemplares similares
-
Social and medical needs of rare metabolic patients: results from a MetabERN survey
por: Sestini, Sylvia, et al.
Publicado: (2021) -
One year of COVID-19: infection rates and symptoms in patients with inherited metabolic diseases followed by MetabERN
por: Paneghetti, Laura, et al.
Publicado: (2022) -
The impact of COVID-19 on rare metabolic patients and healthcare providers: results from two MetabERN surveys
por: Lampe, C., et al.
Publicado: (2020) -
Research activity and capability in the European reference network MetabERN
por: Heard, Jean-Michel, et al.
Publicado: (2019) -
Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network
por: Heard, Jean-Michel, et al.
Publicado: (2020)